| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:12083789 | IVR | 0.000004 M | 0.000004 M | Decreased testis weights | Reproductive endocrine-mediated perturbations |
| IVR | 0.000004 M | 0.000004 M | Affects steroid metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:12773765 | IVR | 10 mg/kg | 10 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations |
| IVR | 10 mg/kg | 10 mg/kg | Affects skeletal development in fetus | Developmental endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Increased placental weights | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg | 2.5 mg/kg | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg | 2.5 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Affects litter size | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Increased placental weights | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Affects skeletal development in fetus | Developmental endocrine-mediated perturbations | |
| PMID:14667468 | IVR | 0.25 mg/kg | 0.25 mg/kg | Decreased thymus gland weights | Immunological endocrine-mediated perturbations |
| IVR | 2.5 mg/kg | 2.5 mg/kg | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg | 2.5 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg | 2.5 mg/kg | Increased spleen weights | Immunological endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg | 2.5 mg/kg | Increase in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg | 2.5 mg/kg | Increased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg | 2.5 mg/kg | Decreased thymus gland weights | Immunological endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg | 2.5 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 0.025 mg/kg | 0.025 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| PMID:16513093 | IVTH | 0.000000001 - 0.00001 M | 0.0000001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| PMID:16613991 | IVR | 0.05 mg/kg | 0.05 mg/kg | Changes in liver morphology | Hepatic endocrine-mediated perturbations |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Alteration in gonadal morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.3 mg/kg | 0.3 mg/kg | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.3 mg/kg | 0.3 mg/kg | Affects thyroid hormone metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Alteration in gonadal morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| PMID:18246498 | IVR | 2.5 mg/kg/day | - | No significant effects observed | - |
| IVR | 0.25 mg/kg/day | - | No significant effects observed | - | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| PMID:20052771 | IVR | 0.17 mg/kg/day | 0.17 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.17 mg/kg/day | 0.17 mg/kg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.17 mg/kg/day | 0.17 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.017 mg/kg/day | 0.017 mg/kg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.017 mg/kg/day | 0.017 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:22362710 | IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations |
| IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| PMID:22972585 | IVR | 0.001 mg/kg | - | No significant effects observed | - |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Undescended testes (or cryptorchidism) | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations | |
| PMID:23523586 | IVTH | 0.000000025 M | 0.000000025 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000005 M | 0.00000005 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000005 M | 0.00000005 M | Affects cytokine signaling | Immunological endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Affects cytokine signaling | Immunological endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:23913619 | IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations |
| IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Induce apoptosis in seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| PMID:2466803 | IVR | 5 - 60 mg/kg | 10 mg/kg | Lymph nodes inflammation | Immunological endocrine-mediated perturbations |
| IVR | 5 - 60 mg/kg | 10 mg/kg | Decreased thymus gland weights | Immunological endocrine-mediated perturbations | |
| IVR | 5 - 60 mg/kg | 35 mg/kg | Decreased spleen weights | Immunological endocrine-mediated perturbations | |
| IVR | 5 - 60 mg/kg | 60 mg/kg | Decreased spleen weights | Immunological endocrine-mediated perturbations | |
| PMID:24895210 | IVR | 10 mg/kg | 10 mg/kg | Affects blood-brain barrier (BBB) | Neurological endocrine-mediated perturbations |
| IVR | 10 mg/kg | 10 mg/kg | Oxidative stress in nervous system | Neurological endocrine-mediated perturbations | |
| IVR | 30 mg/kg | 30 mg/kg | Oxidative stress in nervous system | Neurological endocrine-mediated perturbations | |
| IVR | 30 mg/kg | 30 mg/kg | Affects blood-brain barrier (BBB) | Neurological endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Affects blood-brain barrier (BBB) | Neurological endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Oxidative stress in nervous system | Neurological endocrine-mediated perturbations | |
| PMID:25101840 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Alters thyroglobulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Increase in Thyrotropin-releasing hormone (TRH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Alters thyroglobulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Increase in Thyrotropin-releasing hormone (TRH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Increase in Thyrotropin-releasing hormone (TRH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Alters thyroglobulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| PMID:25819109 | IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations |
| PMID:25898838 | IVR | 4 mg/kg | 4 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations |
| IVR | 4 mg/kg | 4 mg/kg | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| IVR | 8 mg/kg | 8 mg/kg | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| IVR | 8 mg/kg | 8 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations | |
| PMID:27267847 | IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Increased levels of Corticotropin-releasing hormone (CRH) | Neurological endocrine-mediated perturbations |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Alters hypothalamic-pituitary-adrenal (HPA) axis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Increase in corticosterone levels | Neurological endocrine-mediated perturbations | |
| PMID:27521499 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| PMID:28161095 | IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Increased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Alters hypothalamic-pituitary-gonadal axis (HPG axis) | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:28781899 | IVR | 5 mg/kg | 5 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 5 mg/kg | 5 mg/kg | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Reduced glutathione levels | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| PMID:30831249 | IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Affects embryonic development | Developmental endocrine-mediated perturbations |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Oxidative stress in mammary gland | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Increased mammary gland weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Affects lipid metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| PMID:31821856 | IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations |
| PMID:7900160 | IVR | 100 mg/kg | 100 mg/kg | Affects embryonic development | Developmental endocrine-mediated perturbations |
| IVR | 100 mg/kg | 100 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.